Investing.com - Aerovate Therapeutics reported on Monday third quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Aerovate Therapeutics announced earnings per share of $-0.56 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.50 on revenue of $0.
Aerovate Therapeutics 's are down 67% and is trading at $19.37 , still down 30.40% from its 52 week high of $27.83 set on Thursday, August 4, 2022.
Aerovate Therapeutics shares gained 0.05% to trade at $19.37 in intra-day trade the report.
Aerovate Therapeutics follows other major Healthcare sector earnings this month
Aerovate Therapeutics's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar